Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...